Ratings Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE

Equities

PLX

US74365A3095

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 11:24:48 2023-03-21 EDT			5-day change	1st Jan Change
732.5 ^ILa	-.--%		+3.29%	+69.68%

05-10	Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024
05-10	Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's profit outlook over the next few years is a strong asset.
The group's activity appears highly profitable thanks to its outperforming net margins.
Its low valuation, with P/E ratio at 10.25 and 1.95 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PROTALIX BIOTHERAPEUTICS, INC.	+69.68%	90.18M	-
MODERNA, INC.	+67.53%	63.85B	B-
IQVIA HOLDINGS INC.	-0.77%	41.83B	B
LONZA GROUP AG	+44.98%	40.65B	A
CELLTRION, INC.	-10.87%	27.12B	C
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B	B
BIO-TECHNE CORPORATION	+4.70%	12.73B	B+
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B	B+
MEDPACE HOLDINGS, INC.	+27.41%	12.07B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes